

Pomalidomide + low-dose dexamethasone should be considered a standard of care in patients with refractory or relapsed and refractory multiple myeloma regardless of prior treatment

Phase III trial MM-003  
455 patients with refractory or relapsed and refractory multiple myeloma  
after failure of bortezomib and lenalidomide treatment



Investigational treatment:

pomalidomide +  
low-dose dexamethasone

vs

high-dose dexamethasone

Progression-free survival	4.0 months	HR=0.50 p<0.001*	1.9 months
Overall-free survival	13.1 months	HR=0.72 p=0.009*	8.1 months

\*these benefits are generally maintained regardless of the number or type of prior therapies